AI has made precision targeting more powerful than ever — pharma brands can now identify, segment, and personalize outreach to patients and HCPs with a level of granularity that was unimaginable a few years ago. But that same precision is raising uncomfortable questions the industry can no longer sidestep: How much personal data is too much? Where's the line between relevant and invasive? And who's accountable when a "personalized" experience feels like surveillance? This panel brings together voices from brand, compliance, and data strategy to debate the tension at the heart of modern pharma CX — the pressure to deliver hyper-relevant experiences versus the responsibility to protect patient trust and privacy. Expect real disagreement, not a tidy consensus: panelists will challenge each other on where the industry should draw the line, and what happens to brands that get it wrong.
